Related Experiment Video

Updated: Sep 25, 2025

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

758

Thyroid Abnormalities in Heart Failure

Sara Danzi1, Irwin Klein2

  • 1Department of Biological Sciences and Geology, Queensborough Community College, City University of New York, 222-05 56th Avenue, Bayside, NY 11364, USA.

Cardiology Clinics
|April 25, 2022
PubMed

Insights

Thyroid dysfunction impacts heart health. Various heart diseases alter thyroid function, decreasing liothyronine (T3) levels, presenting new challenges for treatment.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Thyroid hormones significantly influence cardiovascular function.
  • Thyroid dysfunction, including hyperthyroidism and hypothyroidism, has well-documented cardiac effects.

Purpose of the Study:

  • To explore the relationship between heart disease and thyroid function.
  • To investigate how various cardiac conditions alter thyroid hormone levels, specifically serum liothyronine (T3).
  • To discuss the pathophysiologic and therapeutic implications of these alterations.

Main Methods:

  • Review of basic science literature.
  • Analysis of clinical data on thyroid function in patients with heart disease.

Main Results:

  • Various heart diseases (congenital, hypertensive, ischemic, post-cardiac surgery, heart transplantation) are associated with altered thyroid function tests.
  • A decrease in serum liothyronine (T3) is a common finding in these conditions.

Conclusions:

  • Alterations in thyroid function tests, particularly decreased T3, are linked to diverse heart diseases.
  • These thyroid changes represent significant pathophysiologic challenges.
  • The findings suggest potential for novel therapeutic strategies targeting thyroid function in cardiac patients.

Keywords:
CardiacCardiovascularLow T(3) syndromeNonthyroidal illnessT(3)Thyroid hormoneTriiodothyronine

More Related Videos

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration10:19

Substernal Thyroid Biopsy Using Endobronchial Ultrasound-guided Transbronchial Needle Aspiration

Published on: November 10, 2014

25.8K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.2K

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
95
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
449
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
44
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
55
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
765